Anavex Life Sciences Corp (AVXL)

[bas2020]

This statement is most incorrect and extremely misguided...

The 30mg and below group was used as placebo in p2a publication comparing to 50mg efficacy, showing how little the company thinks about 30mg efficacy.

Anavex knew that 30mg was as effective as 50mg for certain WT patients.
And the AD P2b/3 trial further revealed this, when Missling stated that 30mg was as effective as 50mg for a significant number of patients. That's GREAT NEWS... and is the reason the combined data was presented at CTAD.

There were no "shortcomings" in the AD P2b/3 trial, that met all endpoints, and no endpoints were "adjusted". To say otherwise is complete FUD nonsense.

We'll see a peer-reviewed journal for AD and PDD later this year. They've been siting on PDD data for a long time and likely have all the AD data by now, too. You can bet that Dr. Jin has everything in place for Rett and perhaps AD NDA fillings around YE.

There's going to be much excitement over the next couple of months!